Macrophages: Orchestrators of Immunity and Therapeutic Targets

Macrophages: Orchestrators of Immunity and Therapeutic Targets

Abstract

Macrophages are a highly diverse and plastic population of innate immune cells that play crucial roles in tissue homeostasis, immunity, and disease pathogenesis. Their ability to perform phagocytosis, antigen presentation, and cytokine production positions them as key regulators of the immune response. This review provides a comprehensive overview of macrophage biology, encompassing their origins, activation states (polarization), diverse functional roles in both innate and adaptive immunity, and their involvement in various disease settings, including cancer, infectious diseases, and autoimmune disorders. Furthermore, we discuss existing and emerging strategies for manipulating and targeting macrophages for therapeutic purposes, such as drug delivery and immunotherapy. A deeper understanding of macrophage heterogeneity, function, and plasticity is essential for developing effective therapies that harness their power to combat disease.

1. Introduction

Macrophages, derived from hematopoietic stem cells and monocytes, are ubiquitous tissue-resident cells that are integral to the immune system and tissue homeostasis. They are not merely scavengers but rather dynamic and versatile cells that respond to a myriad of environmental cues, orchestrating a complex array of functions ranging from phagocytosis and antigen presentation to cytokine production and tissue remodeling. This functional diversity is underpinned by a remarkable plasticity, allowing macrophages to adopt distinct activation states, often referred to as polarization, in response to different stimuli. These diverse activation states dictate the specific roles macrophages play in various physiological and pathological contexts.

Given their central role in immunity and tissue homeostasis, macrophages are critically involved in numerous diseases. In cancer, they can either promote or suppress tumor growth depending on their polarization state and the tumor microenvironment. In infectious diseases, macrophages are essential for pathogen clearance but can also contribute to immunopathology if their response is dysregulated. Similarly, in autoimmune diseases, aberrant macrophage activation can drive chronic inflammation and tissue damage. Therefore, understanding the intricate biology of macrophages and their involvement in disease is crucial for developing effective therapeutic strategies.

The inherent capabilities of macrophages, particularly their phagocytic capacity and ability to traffic to sites of inflammation, make them attractive targets for drug delivery and immunotherapy. By manipulating macrophage function or directing them to specific locations, it is possible to enhance therapeutic efficacy and minimize off-target effects. This review aims to provide a comprehensive overview of macrophage biology, their roles in various diseases, and existing methods for their manipulation and targeting, highlighting the potential for developing innovative macrophage-based therapies.

2. Macrophage Development and Heterogeneity

2.1 Origin and Differentiation

Macrophages originate from hematopoietic stem cells (HSCs) in the bone marrow. Two distinct pathways have been identified for macrophage development. The first involves the differentiation of HSCs into monocytes in the bone marrow, which are then released into the circulation and subsequently migrate into tissues where they differentiate into macrophages. The second pathway involves the in situ proliferation of tissue-resident macrophages, which can self-renew independently of monocytes derived from the bone marrow. Recent studies have shown that both pathways contribute to the macrophage pool in different tissues, with the relative contribution varying depending on the tissue and the inflammatory state.

Monocyte differentiation into macrophages is driven by a complex interplay of transcription factors, including PU.1, MAFB, and C/EBPs. The cytokine macrophage colony-stimulating factor (M-CSF), also known as CSF-1, is essential for the survival, proliferation, and differentiation of monocytes and macrophages. M-CSF signals through its receptor CSF-1R, a tyrosine kinase receptor that activates downstream signaling pathways, including the PI3K/AKT and MAPK pathways, which regulate cell survival, proliferation, and differentiation. Granulocyte-macrophage colony-stimulating factor (GM-CSF) also contributes to monocyte and macrophage development, particularly during inflammation.

2.2 Macrophage Polarization: A Spectrum of Activation States

Macrophages exhibit remarkable plasticity, allowing them to adopt diverse activation states in response to different stimuli. This phenomenon, often referred to as polarization, reflects the ability of macrophages to tailor their function to the specific needs of the tissue and the immune response. The classical model of macrophage polarization distinguishes between two main activation states: M1 and M2 macrophages. However, it is now recognized that macrophage polarization is a more complex process, resulting in a spectrum of activation states rather than distinct binary phenotypes.

• M1 Macrophages (Classical Activation): M1 macrophages are typically induced by interferon-gamma (IFN-γ) and/or lipopolysaccharide (LPS), a component of bacterial cell walls. These macrophages are characterized by the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-12, as well as reactive oxygen species (ROS) and nitric oxide (NO). M1 macrophages are involved in Th1 responses, pathogen clearance, and anti-tumor immunity. They are also characterized by increased expression of MHC class II molecules and costimulatory molecules, enhancing their ability to present antigens to T cells. It’s important to note that unrestrained M1 activation contributes significantly to the cytokine storm seen in severe infections.

• M2 Macrophages (Alternative Activation): M2 macrophages are induced by IL-4, IL-13, IL-10, and TGF-β. These macrophages are characterized by the production of anti-inflammatory cytokines, such as IL-10 and TGF-β, as well as arginase-1, which metabolizes arginine to proline and polyamines, promoting tissue repair and fibrosis. M2 macrophages are involved in Th2 responses, wound healing, and immune regulation. Within the M2 designation, further sub-categorization based on specific inductive signals is common (e.g., M2a, M2b, M2c, M2d). For example, M2a macrophages are induced by IL-4 or IL-13 and play a role in tissue repair and allergy. M2c macrophages are induced by IL-10 or TGF-β and suppress inflammation. M2d macrophages are induced by TLR ligands and promote angiogenesis and tumor growth.

The M1/M2 paradigm, while useful, is an oversimplification of macrophage polarization. In reality, macrophages can express a mixture of M1 and M2 markers, and their activation state can change over time in response to dynamic environmental cues. The specific stimuli present in the microenvironment, the duration of exposure, and the epigenetic modifications of the macrophage genome all contribute to the complexity of macrophage polarization.

Furthermore, recent advances in single-cell technologies, such as single-cell RNA sequencing, have revealed an even greater degree of heterogeneity in macrophage populations, identifying novel macrophage subsets with distinct functional properties. These technologies are providing valuable insights into the dynamic nature of macrophage polarization and the complex interplay between macrophages and their microenvironment. This is critical for understanding how macrophages contribute to both protective and pathogenic processes. Emerging research shows that defining macrophages solely by M1/M2 markers often fails to accurately predict their function in complex environments like the tumor microenvironment.

3. Macrophage Functions in Immunity

Macrophages play a central role in both innate and adaptive immunity through a variety of mechanisms.

3.1 Phagocytosis

Phagocytosis is a fundamental function of macrophages, allowing them to engulf and digest pathogens, cellular debris, and other foreign particles. This process is critical for clearing infections, removing damaged cells, and maintaining tissue homeostasis. Macrophages express a variety of receptors that mediate phagocytosis, including:

• Fc Receptors (FcRs): FcRs bind to the Fc region of antibodies, allowing macrophages to phagocytose opsonized pathogens. Opsonization, the coating of pathogens with antibodies, enhances phagocytosis by providing a specific recognition signal for macrophages.

• Complement Receptors (CRs): CRs bind to complement proteins, such as C3b, which are deposited on the surface of pathogens. Complement activation, a cascade of proteolytic events, leads to the opsonization of pathogens and the recruitment of immune cells.

• Scavenger Receptors (SRs): SRs bind to a variety of modified lipoproteins, polysaccharides, and apoptotic cells. They play a role in clearing cellular debris and preventing the accumulation of toxic substances.

• Dectin-1: Dectin-1 is a pattern recognition receptor (PRR) that binds to β-glucans, a component of fungal cell walls. Dectin-1 activation triggers phagocytosis and the production of pro-inflammatory cytokines.

Following receptor engagement, the macrophage extends pseudopodia around the target particle, engulfing it into a phagosome. The phagosome then fuses with lysosomes, forming a phagolysosome, where the ingested material is degraded by a variety of enzymes, including proteases, lipases, and nucleases. The degraded products are then released into the cytoplasm or presented on MHC class II molecules for antigen presentation.

The efficiency of phagocytosis can be influenced by a variety of factors, including the size and shape of the target particle, the presence of opsonins, and the activation state of the macrophage. For example, M1 macrophages typically exhibit enhanced phagocytic activity compared to M2 macrophages. In addition to direct pathogen clearance, phagocytosis also plays a crucial role in initiating adaptive immune responses through antigen presentation.

3.2 Antigen Presentation

Macrophages are professional antigen-presenting cells (APCs), meaning that they can process and present antigens to T cells, thereby initiating adaptive immune responses. Antigens are processed into small peptides within the macrophage and then loaded onto MHC class II molecules. The MHC class II-peptide complex is then transported to the cell surface, where it can be recognized by CD4+ T cells, also known as helper T cells. CD4+ T cell activation leads to the production of cytokines that further enhance the immune response, including IFN-γ, which activates macrophages and promotes M1 polarization.

Macrophages can also present antigens on MHC class I molecules, although this is less common. MHC class I molecules present antigens derived from the cytoplasm of the cell, including antigens derived from intracellular pathogens, such as viruses. The MHC class I-peptide complex is recognized by CD8+ T cells, also known as cytotoxic T cells, which can kill infected cells. The ability of macrophages to present antigens on both MHC class I and MHC class II molecules allows them to initiate both cellular and humoral immune responses.

Furthermore, macrophages express costimulatory molecules, such as CD80 and CD86, which are essential for T cell activation. These molecules bind to CD28 on T cells, providing a second signal that is required for T cell activation. Without costimulation, T cells may become anergic, meaning that they are unresponsive to antigen stimulation. The expression of costimulatory molecules is upregulated by inflammatory stimuli, such as LPS and IFN-γ, enhancing the ability of macrophages to activate T cells.

3.3 Cytokine Production

Macrophages produce a wide range of cytokines, which are small signaling proteins that regulate the immune response. Cytokines can act on other immune cells, as well as on non-immune cells, influencing their behavior and function. Macrophages produce both pro-inflammatory and anti-inflammatory cytokines, depending on their activation state and the specific stimuli present in the microenvironment.

• Pro-inflammatory Cytokines: These cytokines, such as TNF-α, IL-1β, IL-6, and IL-12, promote inflammation and activate other immune cells. TNF-α and IL-1β are potent activators of the endothelium, increasing vascular permeability and promoting the recruitment of leukocytes to sites of inflammation. IL-6 is a pleiotropic cytokine that has both pro-inflammatory and anti-inflammatory effects. IL-12 is a key cytokine for Th1 responses, promoting the differentiation of CD4+ T cells into IFN-γ-producing cells.

• Anti-inflammatory Cytokines: These cytokines, such as IL-10 and TGF-β, suppress inflammation and promote tissue repair. IL-10 inhibits the production of pro-inflammatory cytokines by macrophages and other immune cells. TGF-β is a potent immunosuppressant that inhibits the proliferation and activation of T cells and other immune cells.

The balance between pro-inflammatory and anti-inflammatory cytokines is critical for regulating the immune response and preventing excessive inflammation. Dysregulation of cytokine production by macrophages can contribute to a variety of diseases, including autoimmune diseases, chronic inflammatory diseases, and cancer. For example, excessive production of TNF-α can contribute to the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Conversely, impaired production of IL-10 can exacerbate inflammation and tissue damage in autoimmune diseases.

4. Macrophage Involvement in Diseases

4.1 Cancer

Macrophages play a complex and often contradictory role in cancer. On the one hand, they can contribute to anti-tumor immunity by directly killing tumor cells, presenting tumor-associated antigens to T cells, and producing pro-inflammatory cytokines that inhibit tumor growth. On the other hand, they can promote tumor growth by suppressing anti-tumor immunity, promoting angiogenesis, and remodeling the extracellular matrix. The role of macrophages in cancer depends on their polarization state, their location within the tumor microenvironment, and the specific characteristics of the tumor.

Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment and are often associated with poor prognosis. TAMs are typically polarized towards an M2-like phenotype, promoting tumor growth and metastasis. They produce immunosuppressive cytokines, such as IL-10 and TGF-β, which inhibit the activity of T cells and other immune cells. They also produce factors that promote angiogenesis, such as VEGF, which supplies the tumor with nutrients and oxygen. Furthermore, TAMs can remodel the extracellular matrix, creating pathways for tumor cells to invade surrounding tissues.

However, it is important to note that not all TAMs are pro-tumorigenic. Some TAMs can exhibit an M1-like phenotype and contribute to anti-tumor immunity. These TAMs can directly kill tumor cells through phagocytosis and the production of cytotoxic molecules, such as TNF-α and NO. They can also present tumor-associated antigens to T cells, initiating anti-tumor immune responses. Strategies to repolarize TAMs from an M2-like to an M1-like phenotype are being actively explored as a potential cancer therapy.

4.2 Infections

Macrophages are essential for controlling infections caused by a wide range of pathogens, including bacteria, viruses, fungi, and parasites. They contribute to pathogen clearance through phagocytosis, antigen presentation, and cytokine production. Macrophages express a variety of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), that recognize pathogen-associated molecular patterns (PAMPs). TLR activation triggers the production of pro-inflammatory cytokines and the activation of downstream signaling pathways that enhance phagocytosis and antigen presentation.

In bacterial infections, macrophages play a critical role in clearing bacteria from the bloodstream and tissues. They phagocytose bacteria and kill them within phagolysosomes. They also produce pro-inflammatory cytokines that recruit other immune cells to the site of infection. However, in some cases, excessive macrophage activation can contribute to immunopathology. For example, in sepsis, excessive production of TNF-α and IL-1β by macrophages can lead to systemic inflammation, organ damage, and death.

In viral infections, macrophages can contribute to both viral clearance and viral pathogenesis. They can phagocytose virus-infected cells and present viral antigens to T cells, initiating anti-viral immune responses. However, some viruses can infect macrophages and replicate within them, leading to macrophage activation and the production of pro-inflammatory cytokines. This can contribute to inflammation and tissue damage. Furthermore, some viruses can use macrophages as a Trojan horse to disseminate throughout the body. HIV, for example, can infect macrophages and be transported to the brain, where it can cause neurological damage.

4.3 Autoimmune Diseases

Macrophages play a critical role in the pathogenesis of autoimmune diseases, which are characterized by an inappropriate immune response against self-antigens. In autoimmune diseases, macrophages can contribute to chronic inflammation and tissue damage by producing pro-inflammatory cytokines, presenting self-antigens to T cells, and activating other immune cells. The specific role of macrophages in autoimmune diseases depends on the specific disease and the target tissue.

In rheumatoid arthritis, macrophages are found in the synovial fluid of affected joints, where they produce pro-inflammatory cytokines, such as TNF-α and IL-1β, which contribute to cartilage and bone destruction. TNF-α inhibitors, which block the activity of TNF-α, are effective therapies for rheumatoid arthritis, demonstrating the importance of macrophages in the pathogenesis of this disease.

In inflammatory bowel disease (IBD), macrophages are found in the intestinal mucosa, where they produce pro-inflammatory cytokines that contribute to chronic inflammation and tissue damage. Macrophages in IBD exhibit impaired phagocytic activity and increased production of pro-inflammatory cytokines.

In multiple sclerosis (MS), macrophages are found in the brain and spinal cord, where they contribute to demyelination and axonal damage. Macrophages in MS can be activated by myelin antigens, leading to the production of pro-inflammatory cytokines and the recruitment of other immune cells to the central nervous system.

5. Macrophage Manipulation and Targeting for Therapy

Given their central role in immunity and disease, macrophages are attractive targets for therapeutic intervention. Strategies to manipulate and target macrophages include drug delivery, immunotherapy, and cell-based therapies. Understanding the complexities of macrophage polarization and function is key to designing effective therapeutic strategies.

5.1 Drug Delivery

Macrophages can be used as vehicles for delivering drugs to specific tissues or cells. Their inherent phagocytic capacity and ability to traffic to sites of inflammation make them ideal for delivering drugs to tumors, infected tissues, and sites of tissue damage. Drugs can be encapsulated in nanoparticles or liposomes and then delivered to macrophages via phagocytosis. Once inside the macrophage, the drug can be released to exert its therapeutic effect.

Targeting macrophages for drug delivery can improve therapeutic efficacy and minimize off-target effects. For example, nanoparticles can be coated with antibodies or ligands that bind to specific receptors on macrophages, enhancing their uptake by macrophages in the target tissue. In cancer, nanoparticles can be targeted to TAMs, delivering chemotherapeutic agents or immunomodulatory drugs directly to the tumor microenvironment. The key challenge is to ensure drug release occurs at the desired location and at an appropriate rate. Premature release can lead to systemic toxicity, while delayed release can reduce therapeutic efficacy.

5.2 Immunotherapy

Macrophages can be manipulated to enhance anti-tumor immunity. Strategies to repolarize TAMs from an M2-like to an M1-like phenotype are being actively explored as a potential cancer therapy. This can be achieved by blocking the signals that promote M2 polarization, such as IL-10 and TGF-β, or by stimulating the signals that promote M1 polarization, such as IFN-γ and TLR ligands. In addition, macrophages can be engineered to express chimeric antigen receptors (CARs), similar to CAR-T cells. CAR-macrophages can be targeted to tumor-associated antigens, allowing them to specifically kill tumor cells. Clinical trials are underway to evaluate the safety and efficacy of CAR-macrophage therapy in cancer.

Another approach to macrophage-based immunotherapy is to enhance their antigen-presenting capacity. Macrophages can be loaded with tumor-associated antigens and then injected back into the patient, stimulating anti-tumor T cell responses. This approach has shown promise in preclinical studies and is being evaluated in clinical trials. However, the immunosuppressive tumor microenvironment can limit the effectiveness of macrophage-based immunotherapy. Strategies to overcome immunosuppression, such as combining macrophage-based immunotherapy with checkpoint inhibitors, are being explored. Specifically, therapies targeting the CD47-SIRPα axis, which inhibits macrophage phagocytosis of tumor cells, show significant promise.

5.3 Cell-Based Therapies

Macrophages can be used as cell-based therapies to treat a variety of diseases. Macrophages can be isolated from the patient’s blood or bone marrow, expanded in vitro, and then injected back into the patient to treat inflammatory diseases, infectious diseases, and tissue damage.

In inflammatory diseases, macrophages can be engineered to produce anti-inflammatory cytokines, such as IL-10 and TGF-β, which can suppress inflammation and promote tissue repair. In infectious diseases, macrophages can be engineered to express antimicrobial peptides or antibodies, enhancing their ability to kill pathogens. In tissue damage, macrophages can be engineered to produce growth factors and matrix remodeling enzymes, promoting tissue regeneration.

A key challenge in cell-based macrophage therapy is to ensure that the injected macrophages home to the target tissue and survive long enough to exert their therapeutic effect. Strategies to improve macrophage homing and survival include modifying their surface receptors and delivering them in biocompatible scaffolds. Furthermore, the donor source of macrophages must be carefully considered to minimize the risk of immune rejection.

6. Conclusion

Macrophages are highly versatile and plastic cells that play crucial roles in immunity and tissue homeostasis. Their ability to perform phagocytosis, antigen presentation, and cytokine production positions them as key regulators of the immune response. Macrophages are involved in a wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. Understanding the intricate biology of macrophages and their involvement in disease is crucial for developing effective therapeutic strategies. Macrophage-targeted therapies, including drug delivery, immunotherapy, and cell-based therapies, hold great promise for treating a variety of diseases. Future research should focus on further elucidating the complex mechanisms that regulate macrophage polarization and function, as well as developing novel strategies to manipulate and target macrophages for therapeutic benefit.

References

1. Gordon, S., & Taylor, P. R. (2005). Monocyte and macrophage heterogeneity. Nature Reviews Immunology, 5(12), 953-964.
2. Murray, P. J., Allen, J. E., Biswas, S. K., Chan, T., Doherty, C., Donohue, K. D., … & Vogel, L. A. (2014). Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 41(1), 14-20.
3. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology, 25(12), 677-686.
4. Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8(12), 958-969.
5. Italiani, P., & Boraschi, D. (2014). From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Frontiers in Immunology, 5, 514.
6. Hume, D. A. (2015). Macrophages as APC and the dendritic cell myth. Journal of Immunology, 194(7), 3011-3017.
7. DeNardo, D. G., & Ruffell, B. (2019). Macrophages as regulators of tumour immunity and immunotherapy. Nature Reviews Immunology, 19(6), 369-382.
8. Aran, D., Hu, Z., Butrus, S., Lissner, M. M., Crotty, S., Peters, B., & Khatri, P. (2017). xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biology, 18(1), 220.
9. Davies, L. C., Jenkins, S. J., Allen, J. E., & Taylor, P. R. (2013). Tissue-resident macrophages. Nature Immunology, 14(10), 986-995.
10. Wynn, T. A., Chawla, A., & Pollard, J. W. (2013). Macrophage biology in development, homeostasis and disease. Nature, 496(7446), 445-455.
11. Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 11(10), 889-896.
12. Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39-51.
13. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239-252.
14. Gordon, S. (2003). Phagocytosis: multiple mechanisms. Nature Reviews Immunology, 3(1), 23-35.
15. Uribe-Querol, E., Rosales, C. (2020). Phagocytosis: Our Current Understanding of a Universal Biological Process. Frontiers in Immunology, 11, 1066.
16. van Dalen, R., van der Meer, J. W. M., & Adema, G. J. (2019). Dectin-1-Mediated Immunotherapy. Frontiers in Immunology, 10, 209.
17. Hussain, S. A., Leoni, F., Blackburn, E., Manek, S., Davies, D. R., & Dive, C. (2006). Systemic tumor-targeted delivery of TRAIL using monocytes. Cancer Research, 66(6), 3362-3370.
18. Gu, B., Swartz, M. A., & Hubbell, J. A. (2015). Injectable, porous, and cell-instructive hydrogels for cartilage repair. Advanced Healthcare Materials, 4(8), 1245-1252.
19. Anderson, N. R., Minutoli, L., & Thomas, R. (2017). Macrophage migration inhibitory factor (MIF): a critical regulator of inflammation. Frontiers in Immunology, 8, 680.
20. Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical Cancer Research, 21(4), 687-692.
21. Willingham, S. B., Volkmer, A. K., Gentles, A. J., Senger, R. C., Miklos, D., & Chao, M. P. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences, 109(17), 6662-6667.